Inventiva (IVA) Return on Sales (2019 - 2021)

Inventiva (IVA) posted quarterly Return on Sales of 1.52% for Q2 2021, down 33.0% year-over-year from 2.27% in Q2 2020, and down 205.59% quarter-over-quarter from 0.5% in Q1 2021.

Inventiva (IVA) Return on Sales (2019 - 2021) Analysis & Trends

Inventiva's Return on Sales history runs 3 years deep, the most recent figure standing at 1.52% for Q2 2021.

  • In Q2 2021, Return on Sales fell 33.0% year-over-year to 1.52%; the TTM figure through Jun 2021 stood at 0.89% (changed N/A YoY), while the FY2025 annual figure was 0.45%, down 45.0% from the prior year.
  • Return on Sales for Q2 2021 stood at 1.52%, down from 0.5% in the prior quarter.
  • The five-year high for Return on Sales was 0.04% in Q4 2019, with the low at 1.52% in Q2 2021.
  • The 3-year median for Return on Sales is 0.79% (2020), against an average of 0.8%.
  • The sharpest annual moves came in 2020 and 2021: Return on Sales tumbled 76 bps in 2020, then rose 28 bps in 2021.
  • Inventiva's Return on Sales stood at 0.04% in 2019, then slumped by 1757 bps to 0.8% in 2020, then slumped by 90 bps to 1.52% in 2021.
  • Business Quant data shows IVA's Return on Sales at 1.52% in Q2 2021, 0.5% in Q1 2021, and 0.8% in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 0.00%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 0.00%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 0.00%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 0.00%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 0.00%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 0.00%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 0.00%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 0.00%
10 Inventiva 888.89 Mn 888.89 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2021 -1.52%
Mar 31, 2021 -0.50%
Dec 31, 2020 -0.80%
Jun 30, 2020 -1.19%
Mar 31, 2020 -0.78%
Dec 31, 2019 -0.04%